Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

University Medical Center Goettingen

- PMLiVE

Newel Health launches study of digital therapeutic for Parkinson’s disease

The Soturi app is designed to optimise personalised treatment plans for patients

- PMLiVE

Sanofi and AI specialist Aqemia enter $140m drug discovery partnership

The deal is aimed at discovering small molecule drugs across several therapeutic areas

- PMLiVE

Almirall, BSC and Nostrum Biodiscovery partner for dermatological diseases

The collaboration will aim to find new therapies for dermatological diseases through AI

- PMLiVE

AstraZeneca and generative AI company Absci enter $247m oncology partnership

The collaboration is aimed at developing an AI-designed antibody drug for an oncology target

- PMLiVE

Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership

The collaboration will see Boehringer use an IBM-developed AI model to boost its drug discovery efforts

Can Cinderella save us?

Study finds AI detects AMR faster than gold-standard testing

The method detected AMR with at least 80% accuracy on a per-cell basis, within 30 minutes

- PMLiVE

Healthcare in the age of AI: How will artificial intelligence impact future decision-making?

Authored by: Constanza Salas, Jhon Galindo and Rachel Howard

Research Partnership

- PMLiVE

Levofloxacin revealed as first effective treatment for multi-drug resistant TB

UCL researchers found that levofloxacin prevented MDR-TB by 60%

- PMLiVE

AstraZeneca announces launch of new healthtech business Evinova to optimise clinical trials

Evinova aims to meet the needs of patients, healthcare professionals and regulators

- PMLiVE

Almirall and Absci announce $650m AI dermatological drug discovery partnership

The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology

- PMLiVE

Spinal stimulation implant offers new hope for Parkinson’s disease treatment

The implant was tested to correct gait disorders associated with advanced cases of the disease

- PMLiVE

AbbVie’s Parkinson’s disease therapy recommended by NICE for advanced disease

Around 900 adults with advanced Parkinson’s are set to benefit from Produodopa

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links